BR112014000259A2 - bloqueadores de canais de sódio dependentes de voltagem - Google Patents

bloqueadores de canais de sódio dependentes de voltagem

Info

Publication number
BR112014000259A2
BR112014000259A2 BR112014000259A BR112014000259A BR112014000259A2 BR 112014000259 A2 BR112014000259 A2 BR 112014000259A2 BR 112014000259 A BR112014000259 A BR 112014000259A BR 112014000259 A BR112014000259 A BR 112014000259A BR 112014000259 A2 BR112014000259 A2 BR 112014000259A2
Authority
BR
Brazil
Prior art keywords
voltage
sodium channel
channel blockers
dependent sodium
dependent
Prior art date
Application number
BR112014000259A
Other languages
English (en)
Inventor
Lin Guoliang
Nie Hong
Charles Boehm Jeffrey
Kerns Jeffrey
D Murdoch Robert
S Davis Roderick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47437403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014000259(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112014000259A2 publication Critical patent/BR112014000259A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014000259A 2011-07-06 2012-07-03 bloqueadores de canais de sódio dependentes de voltagem BR112014000259A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505075P 2011-07-06 2011-07-06
PCT/US2012/045350 WO2013006596A1 (en) 2011-07-06 2012-07-03 Voltage-gated sodium channel blockers

Publications (1)

Publication Number Publication Date
BR112014000259A2 true BR112014000259A2 (pt) 2017-02-14

Family

ID=47437403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000259A BR112014000259A2 (pt) 2011-07-06 2012-07-03 bloqueadores de canais de sódio dependentes de voltagem

Country Status (20)

Country Link
US (1) US20140121213A1 (pt)
EP (1) EP2729149A4 (pt)
JP (1) JP2014518281A (pt)
KR (1) KR20140059774A (pt)
CN (1) CN103764148A (pt)
AR (1) AR087053A1 (pt)
AU (1) AU2012279091A1 (pt)
BR (1) BR112014000259A2 (pt)
CA (1) CA2840394A1 (pt)
CL (1) CL2014000020A1 (pt)
CO (1) CO6821963A2 (pt)
CR (1) CR20140002A (pt)
DO (1) DOP2014000001A (pt)
EA (1) EA201490210A1 (pt)
MA (1) MA35336B1 (pt)
MX (1) MX2014000112A (pt)
PE (1) PE20141385A1 (pt)
TW (1) TW201302707A (pt)
WO (1) WO2013006596A1 (pt)
ZA (1) ZA201309533B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
BR112015022385A2 (pt) * 2013-03-14 2017-07-18 Daiichi Sankyo Co Ltd droga para uma doença respiratória
WO2018017896A1 (en) 2016-07-20 2018-01-25 Amgen Inc. Pyridine sulfonamides
CN109796402A (zh) * 2018-12-28 2019-05-24 京博农化科技有限公司 一种烟嘧磺隆中间体2-氯-n,n-二甲基烟酰胺的制备方法
WO2023049364A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147864A2 (en) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers

Also Published As

Publication number Publication date
AR087053A1 (es) 2014-02-12
WO2013006596A1 (en) 2013-01-10
CA2840394A1 (en) 2013-01-10
EP2729149A4 (en) 2015-01-07
MX2014000112A (es) 2014-01-31
CN103764148A (zh) 2014-04-30
MA35336B1 (fr) 2014-08-01
CL2014000020A1 (es) 2014-08-01
ZA201309533B (en) 2014-08-27
CR20140002A (es) 2014-03-05
TW201302707A (zh) 2013-01-16
PE20141385A1 (es) 2014-10-29
DOP2014000001A (es) 2014-04-30
CO6821963A2 (es) 2013-12-31
JP2014518281A (ja) 2014-07-28
EA201490210A1 (ru) 2014-05-30
EP2729149A1 (en) 2014-05-14
KR20140059774A (ko) 2014-05-16
US20140121213A1 (en) 2014-05-01
AU2012279091A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
NL301181I2 (nl) eptinezumab
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
DK2769050T3 (da) Propsensor
BR112013024527A2 (pt) pessário
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
UA23983S (uk) Навушник
BR112014011011A2 (pt) seções de estrutura de poços
DK3141251T3 (da) Koloskopi - forberedelse
BR112014000259A2 (pt) bloqueadores de canais de sódio dependentes de voltagem
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DE112011105343A5 (de) Kommunikationsgerät
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
UA23002S (uk) Ніж
ES2404690B1 (es) Quitanieves avanzado
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren
FI9572U1 (fi) Tietoliikennejärjestely
DOS2011000357S (es) Cubitos de caldo (caldos)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]